Ratings HealthCare Global Enterprises Limited Bombay S.E.

Equities

HCG

INE075I01017

Market Closed - Bombay S.E. Other stock markets 06:00:53 2024-07-01 EDT			5-day change	1st Jan Change
377.5 ^INR	-0.67%		-1.15%	+3.24%

06-28	HealthCare Global Enterprises to Acquire Vizag Hospital	MT
06-28	HealthCare Global Enterprises Limited entered into share purchase agreement to acquire 51% stake in Vizag Hospital and Cancer Research Centre Private Limited for INR 2.1 billion.	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

Strengths

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses

The company does not generate enough profits, which is an alarming weak point.
With an expected P/E ratio at 133.45 and 58.74 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
In relation to the value of its tangible assets, the company's valuation appears relatively high.
The valuation of the company is particularly high given the cash flows generated by its activity.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' opinions have been revised negatively.
Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Healthcare Facilities & Services

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
HEALTHCARE GLOBAL ENTERPRISES LIMITED	+3.24%	635M		B
HCA HEALTHCARE, INC.	+18.69%	84.15B		C+
CVS HEALTH CORPORATION	-25.20%	74.14B		B-
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	-0.35%	26.77B		C+
LABCORP HOLDINGS INC.	-10.46%	17.15B		B
FRESENIUS SE & CO. KGAA	+0.36%	16.83B		A-
QUEST DIAGNOSTICS INCORPORATED	-0.73%	15.21B		A-
NATERA, INC.	+72.88%	13.3B		C-
TENET HEALTHCARE CORPORATION	+76.04%	12.99B		C+
PURE HEALTH HOLDING	-25.61%	12.79B	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes